The rise of Viagra and its impact on the drug landscape presents a complicated question for shareholders. While the initial sales statistics were remarkable, the intellectual property has expired, leading to a wave of copycat alternatives that are eroding revenue. In addition, the market is facing challenges related to aging trends and shifting … Read More